Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder

Trial Profile

Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Aug 2018

At a glance

  • Drugs Riluzole (Primary)
  • Indications Social phobia
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 16 Aug 2018 According to Biohaven Pharmaceuticals media release, the company expects to present additional results from this trial at upcoming scientific meetings over the next year. Based upon these trial results, Biohaven plans to expand its glutamate modulating platform development program to include the treatment of Generalized anxiety disorder (GAD).
    • 16 Aug 2018 Primary endpoint has been met. (VAS-anxiety after the impromptu speech task), as reported in a Biohaven Pharmaceuticals media release.
    • 16 Aug 2018 Status changed from recruiting to active, no longer recruiting, as reported in a Biohaven Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top